Eva Hoke

940 citations
31 papers · 714 · h-index 14

Impact in

  • Hematology top 2%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 10%
    • Chronic Lymphocytic Leukemia Research

Papers in

Co-authors
Richard A. Larson (18 shared papers)Bayard L. Powell (14 shared papers)Thomas C. Shea (8 shared papers)Clara D. Bloomfield (12 shared papers)Wendy Stock (12 shared papers)Jonathan E. Kolitz (8 shared papers)Stephen L. George (5 shared papers)Steven L. Allen (5 shared papers)
Journals
Blood (14 papers)Journal of Clinical Oncology (3 papers)Journal of Competitiveness (1 paper)British Journal of Haematology (1 paper)Haematologica (1 paper)
Partner nations
United StatesCzechiaUnited Kingdom

In The Last Decade

Eva Hoke

28 papers receiving 697 citations

Peers

Eva Hoke
Comparison fields: 5 of 74
  • Hematology 369
  • Genetics 142
  • Oncology 219
  • Public Health, Environmental and Occupational Health 229
  • Pathology and Forensic Medicine 139
Replace Susana Vives with:
Susana Vives Spain
Bhavana Bhatnagar United States
Salvatore Palmieri Italy
Harish G. Ahuja United States
Emily Curran United States
Olga Salamero Spain
Arlin Za United States
Jan Maxwell Nørgaard Denmark
M. Hensel Germany
S. Faderl United States
Eva Hoke relative to Susana Vives Spain Susana Vives's profile →
Citations per field
00.5×2×2.8×
Susana Vives · 1×
Citations per year

Countries citing papers authored by Eva Hoke

Since Specialization
Citations

This map shows the geographic impact of Eva Hoke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hoke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hoke more than expected).

Fields of papers citing papers by Eva Hoke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hoke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hoke. The network helps show where Eva Hoke may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Hoke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Hoke Line = papers co-authored together Eva Hoke links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
Journal of Clinical Oncology ·Jonathan E. Kolitz, Stephen L. George, Richard K. Dodge, David D. Hurd, Bayard L. Powell, Steven L. Allen, E Vélez-García, Joseph O. Moore, Thomas C. Shea, Eva Hoke, Michael A. Caligiuri, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
2004118
2
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Blood ·Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hárs, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, (unknown)
201095
3
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)
Haematologica ·Meir Wetzler, D. Watson, Wendy Stock, Greg Koval, Flora Mulkey, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, C. D. Bloomfield, Claudia Linker, Richard A. Larson
201374
4
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
Journal of Clinical Oncology ·Thomas S. Lin, Kathleen Donohue, John C. Byrd, Margaret S. Lucas, Eva Hoke, Elizabeth M. Bengtson, (unknown), James N. Atkins, Brian K. Link, Richard A. Larson
201064
5
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
Leukemia ·William Blum, Ben L. Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey L. Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Eunice S. Wang, Eva Hoke, Krzysztof Mrózek, Jessica Kohlschmidt, Clara D. Bloomfield, Susan Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson
201662
6
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
British Journal of Haematology ·David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson
201461
7
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).
Blood ·Wendy Stock, Ben L. Sanford, Gerard Lozanski, Ravi Vij, John C. Byrd, Bayard L. Powell, Meir Wetzler, Dorie Sher, Colin G. Edwards, Michael E. Kelly, Sue Richards, Crystal Sung, Greg Malnassy, Eva Hoke, Clara D. Bloomfield, Richard A. Larson
200953
8
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.
Blood ·Jonathan E. Kolitz, Vera Hárs, Daniel J. DeAngelo, Steven L. Allen, Thomas C. Shea, Ravi Vij, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Stephen L. George, Richard A. Larson
200722
9
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808
Cancer ·Jonathan E. Kolitz, Stephen L. George, Don M. Benson, Kati Maharry, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Courtney E. Bakan, Vera Hárs, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Richard A. Larson
201321
10
Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002
Blood ·David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, Richard A. Larson
201020
11
Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results
Blood ·Peter M. Voorhees, Flora Mulkey, Hani Hassoun, Claudia E. Paba‐Prada, Yvonne A. Efebera, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera J. Suman, Paul G. Richardson
201519
12
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Blood Advances ·John C. Byrd, Amy S. Ruppert, Nyla A. Heerema, Alese E. Halvorson, Eva Hoke, Mitchell R. Smith, John E. Godwin, Stephen Couban, Todd A. Fehniger, Michael J. Thirman, Martin S. Tallman, Frederick R. Appelbaum, Richard M. Stone, Sue Robinson, (unknown), Sumithra J. Mandrekar, Richard A. Larson
201816
13
A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.
Blood ·Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas C. Shea, Wendy Stock, Vera Hárs, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
200515
14
Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).
Blood ·Wendy Stock, Daohai Yu, Ben L. Sanford, Gerard Lozanski, Spero R. Cataland, Ravi Vij, John C. Byrd, Bayard L. Powell, Meir Wetzler, Maher Albitar, Dorie Sher, Colin G. Edwards, Eva Hoke, Clara D. Bloomfield, Richard A. Larson
200514
15
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.
Blood ·Thomas S. Lin, Kathleen Donohue, John C. Byrd, Margaret S. Lucas, Eva Hoke, Elizabeth M. Bengtson, James N. Atkins, Brian K. Link, (unknown), (unknown)
200912
16
Competitiveness of the Regions in the Czech Republic from the Perspective of Disaster Risk Financing
Journal of Competitiveness ·Alena Oulehlová, Aleš Kudlák, Rudolf Urban, Eva Hoke
20218
17
CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure
Blood ·Ravi Vij, Vera Hárs, William Blum, Tsiporah B. Shore, Aaron P. Rapoport, Thomas C. Shea, Eva Hoke, Richard M. Stone, Paula N. Friedman, Kouros Owzar, Steven M. Devine
20147
18
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)
Blood ·William Blum, Ben L. Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey L. Uy, Bayard L. Powell, Wendy Stock, Maria R. Baer, Jonathan E. Kolitz, Meir Wetzler, Eva Hoke, Clara D. Bloomfield, Susan M. Geyer, Guido Marcucci, Richard M. Stone, Richard A. Larson
20126
19
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)
Blood ·Meir Wetzler, Dorothy Watson, Wendy Stock, Kouros Owzar, Gregory Koval, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Guido Marcucci, Clara D. Bloomfield, Charles Linker, Richard A. Larson
20125
20
Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001.
Blood ·Meir Wetzler, Wendy Stock, Kathleen Donohue, Kouros Owzar, Dorie A. Sher, Eva Hoke, John M. McCarty, William Blum, Bayard L. Powell, Clara D. Bloomfield, Charles Linker, Richard A. Larson
20074

About Eva Hoke

Eva Hoke is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Genetics, Pathology and Forensic Medicine and Oncology, having authored 31 papers that have together received 714 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (12 papers), Chronic Lymphocytic Leukemia Research (11 papers), Acute Myeloid Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Business and Economic Development (2 papers), Hematopoietic Stem Cell Transplantation (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). The work is most often cited by research in Hematology (369 citations), Genetics (142 citations), Oncology (219 citations), Public Health, Environmental and Occupational Health (229 citations) and Pathology and Forensic Medicine (139 citations). Eva Hoke has collaborated with scholars based in United States, Czechia and United Kingdom. Frequent co-authors include Richard A. Larson, Bayard L. Powell, Thomas C. Shea, Clara D. Bloomfield, Wendy Stock, Jonathan E. Kolitz, Stephen L. George, Steven L. Allen, Guido Marcucci and Ravi Vij. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Competitiveness, British Journal of Haematology and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susana VivesBreakdown of academic impact, for papers by Bhavana BhatnagarBreakdown of academic impact, for papers by Salvatore PalmieriBreakdown of academic impact, for papers by Harish G. AhujaBreakdown of academic impact, for papers by Emily CurranBreakdown of academic impact, for papers by Olga SalameroBreakdown of academic impact, for papers by Arlin ZaBreakdown of academic impact, for papers by Jan Maxwell NørgaardBreakdown of academic impact, for papers by M. HenselBreakdown of academic impact, for papers by S. Faderl